U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C34H63ClN2O6S
Molecular Weight 663.392
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLINDAMYCIN PALMITATE

SMILES

[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@H](C)Cl)[C@@]2([H])O[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@H]2O

InChI

InChIKey=OYSKUZDIHNKWLV-PRUAPSLNSA-N
InChI=1S/C34H63ClN2O6S/c1-6-8-9-10-11-12-13-14-15-16-17-18-19-21-27(38)42-32-30(40)29(39)31(43-34(32)44-5)28(24(3)35)36-33(41)26-22-25(20-7-2)23-37(26)4/h24-26,28-32,34,39-40H,6-23H2,1-5H3,(H,36,41)/t24-,25+,26-,28+,29+,30-,31+,32+,34+/m0/s1

HIDE SMILES / InChI

Molecular Formula C34H63ClN2O6S
Molecular Weight 663.392
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CLEOCIN HYDROCHLORIDE
Curative
CLEOCIN HYDROCHLORIDE
Curative
CLEOCIN HYDROCHLORIDE
Curative
CLEOCIN HYDROCHLORIDE
Curative
CLEOCIN HYDROCHLORIDE
Curative
CLEOCIN HYDROCHLORIDE
Curative
CLEOCIN HYDROCHLORIDE
Curative
CLEOCIN T
Curative
CLEOCIN PHOSPHATE
Curative
CLEOCIN PHOSPHATE
Curative
CLEOCIN PHOSPHATE
Curative
CLEOCIN PHOSPHATE
Curative
CLEOCIN PHOSPHATE
Curative
CLEOCIN PHOSPHATE

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 μg/mL
600 mg single, oral
CLINDAMYCIN plasma
Homo sapiens
0.92 ng/mL
0.03 g 1 times / day steady-state, topical
CLINDAMYCIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
12.2 μg × h/mL
600 mg single, oral
CLINDAMYCIN plasma
Homo sapiens
13.54 ng × h/mL
0.03 g 1 times / day steady-state, topical
CLINDAMYCIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
600 mg single, oral
CLINDAMYCIN plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Sample Use Guides

In Vivo Use Guide
150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration: Oral
In Vitro Use Guide
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Substance Class Chemical
Record UNII
C501Z28AFG
Record Status Validated (UNII)
Record Version